A Phase 2/3 interventional study of WSE and Placebo Oral Tablet in Schizophrenia, sponsored by Chengappa, K.N. Roy, MD. Terminated at 2 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2024-10-08.
Sponsored by Chengappa, K.N. Roy, MD · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,466 studies in Schizophrenia with a site in United States — 148 open to participants now, 166 under way, 22 of them phase 3. Schizophrenia · United States.
Among the 1,466 studies in Schizophrenia with a site in United States, this one is the 818th largest by enrollment of the 1,320 interventional ones that give a count, is one of 48 that started in 2018, is one of 22 in phase 2/3, and was the 1,054th registered.
3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.
Browse Schizophrenia studies →148 of the 1,466 studies in Schizophrenia with a site in United States are open now. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18–59 · Healthy volunteers
Washington University School of Medicine · Sites in United States
Ages 18–59 · Healthy volunteers
University of California, San Diego · Sites in United States
Ages 18–55
Novartis Pharmaceuticals · Sites in United States
Ages 18–65
Stanford University · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,466 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 228 · Phase 2 271 · Phase 3 218 · Phase 4 193
First in 1983; this study’s year is marked. 48 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 47 is below the median of 70 across 2,953 interventional studies indexed under Schizophrenia.
Median enrollment 66 across the 1,320 interventional studies, 163 across the 128 observational. Of the 1,234 that completed or were terminated, 603 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
517 of 1,466 have an industry lead sponsor. The 10 most frequent:
Chengappa, K.N. Roy, MD is the lead sponsor of 2 studies on the registry; none are open to participants now.
Chengappa, K.N. Roy, MD has 1 study filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
52 of the studies in Schizophrenia with a site in United States that are under way reach primary completion within a year, 9 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06482554Phase 3Louisiana State University Health Sciences Center ShreveportLumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. | 2026-12 |
| NCT03817502Phase 3Gedeon Richter Plc.Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia | 2026-12-15 |
| NCT06191965Phase 3Mclean HospitalMitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction | 2027-01-31 |
| NCT07184619Phase 3Newron Pharmaceuticals SPAEvenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia | 2027-03-31 |
| NCT07363577Phase 3LB Pharmaceuticals Inc.Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia | 2027-06 |
Add all 52 to your calendar (.ics) → With an account.
Among the 1,466 studies in Schizophrenia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To determine whether a standardized extract of Withania somnifera will reduce psychopathology scores (PANSS total score) in persons with schizophrenia. A secondary aim is to determine whether WSE reduces measures of positive and negative symptoms (PANSS subscales) and stress scores on the Perceived Stress Scale (PSS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
WSE 500 mg bid for 12 weeks
Drug: WSE
Placebo oral tablet bid for 12 weeks
Drug: Placebo Oral Tablet
WSE tablets
Also known as: Withania somnifera extracts, Ashwagandha, Sensoril®
Placebo tablet
Positive and Negative Symptom Scale
The Positive and Negative Syndrome Scale (PANSS) is a medical scale used for measuring symptom severity of patients with schizophrenia. To assess a patient using PANSS, an approximately 45-minute clinical interview is conducted. The patient is rated from 1 to 7 on 30 different symptoms based on the interview as well as reports of family members or primary care hospital workers. Subjects can not score lower than 30 or higher than 210. Higher score indicates higher amount of psychopathology
Time frame: 12 weeks
PANSS Negative Factor Score Also Know as Marder Factors
The Marder negative factor is a factor-analysis derived dimension of the Positive and Negative Syndrome Scale (PANSS) that measures negative symptoms of schizophrenia. It's made up of seven items from the PANSS, including: Blunted affect, Emotional withdrawal, Poor rapport, Passive/apathetic withdrawal, Motor retardation, Active social avoidance, Lack of spontaneity in conversation. Each item is scored from 1 to 7 with a higher score indicating greater severity. Minimum score is 7 and maximum is 49
Time frame: 12 weeks
| Milestone | Withania Somnifera Extract (WSE) | Placebo Tablets |
|---|---|---|
| Started | 24 | 23 |
| Completed | 20 | 19 |
| Not completed | 4 | 4 |
The Positive and Negative Syndrome Scale (PANSS) is a medical scale used for measuring symptom severity of patients with schizophrenia. To assess a patient using PANSS, an approximately 45-minute clinical interview is conducted. The patient is rated from 1 to 7 on 30 different symptoms based on the interview as well as reports of family members or primary care hospital workers. Subjects can not score lower than 30 or higher than 210. Higher score indicates higher amount of psychopathology
| score on a scale | Withania Somnifera Extract (WSE) | Placebo Tablets |
|---|---|---|
| Week 0 | 65.0 ± 2.6 | 75.1 ± 2.6 |
| Week 6 | 63.2 ± 2.4 | 72.0 ± 2.5 |
| Week 12 | 61.3 ± 2.7 | 68.8 ± 2.7 |
The Marder negative factor is a factor-analysis derived dimension of the Positive and Negative Syndrome Scale (PANSS) that measures negative symptoms of schizophrenia. It's made up of seven items from the PANSS, including: Blunted affect, Emotional withdrawal, Poor rapport, Passive/apathetic withdrawal, Motor retardation, Active social avoidance, Lack of spontaneity in conversation. Each item is scored from 1 to 7 with a higher score indicating greater severity. Minimum score is 7 and maximum is 49
| score on a scale | Withania Somnifera Extract (WSE) | Placebo Tablets |
|---|---|---|
| Baseline | 2.05 ± .84 | 2.68 ± .67 |
| 12 weeks | 2.10 ± .80 | 2.45 ± .69 |
Collected over 12 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Withania Somnifera Extract (WSE) | 0/24 (0%) | 1/24 (4.2%) | 12/24 (50%) |
| Placebo Tablets | 0/23 (0%) | 3/23 (13%) | 18/23 (78.3%) |
| Event | Withania Somnifera Extract (WSE) | Placebo Tablets |
|---|---|---|
| Suicidal ideationPsychiatric disorders | 1/24 | 2/23 |
| COVID 19Infections and infestations | 0/24 | 1/23 |
| Event | Withania Somnifera Extract (WSE) | Placebo Tablets |
|---|---|---|
| Objective tinnitusEar and labyrinth disorders | 0/24 | 2/23 |
| ConstipationGastrointestinal disorders | 2/24 | 1/23 |
| NauseaGastrointestinal disorders | 2/24 | 1/23 |
| Abdominal painGastrointestinal disorders | 1/24 | 1/23 |
| DiarrheaGastrointestinal disorders | 0/24 | 1/23 |
| Dry MouthGastrointestinal disorders | 1/24 | 1/23 |
| Nausea and vomitingGastrointestinal disorders | 1/24 | 1/23 |
| FatigueGeneral disorders | 0/24 | 1/23 |
| EndometritisInfections and infestations | 0/24 | 1/23 |
| Upper Respiratory InfectionInfections and infestations | 0/24 | 1/23 |
| Age, Continuous(years) | Withania Somnifera Extract (WSE) | Placebo Tablets | Total |
|---|---|---|---|
| Mean | 43.7 ± 10.9 | 43.8 ± 12.1 | 43.7 ± 11.4 |
| Sex: Female, Male(Participants) | Withania Somnifera Extract (WSE) | Placebo Tablets | Total |
|---|---|---|---|
| Female | 6 | 3 | 9 |
| Male | 18 | 20 | 38 |
| Ethnicity (NIH/OMB)(Participants) | Withania Somnifera Extract (WSE) | Placebo Tablets | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 3 |
| Not Hispanic or Latino | 22 | 21 | 43 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Withania Somnifera Extract (WSE) | Placebo Tablets | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 5 | 9 | 14 |
| White | 16 | 12 | 28 |
| More than one race | 2 | 1 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Deidentified will be submitted an NIH repository
Ran from Dec 2018 to primary completion in Jun 2023, 54 months.
Results were first posted in Oct 2024, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ashwagandha
Chengappa, K.N. Roy, MD